Stock Market

Biogen gets FDA nod for high-dose Spinraza treatment

By Bullbit Editorial · March 30, 2026

WhatBiogen receives FDA approval for high-dose Spinraza regimen
WhyThis approval marks a significant milestone in the treatment of rare neurological disorders
SignalStrong clinical data supports the efficacy and safety of the high-dose regimen
TargetThe FDA approval targets patients with severe forms of spinal muscular atrophy
RiskThe high-dose regimen may pose increased risks of side effects compared to standard treatment